ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1074

A Multi-Omics Approach to Renal Epithelial Senescence Urinary Biomarker Discovery

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Baird, David Paul, The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom
  • Reck, Maximilian, The University of Edinburgh The Queen's Medical Research Institute, Edinburgh, Edinburgh, United Kingdom
  • Campbell, Ross Alexander, The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom
  • O Sullivan, Eoin D., The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom
  • Docherty, Marie, The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom
  • Traynor, Jamie P., University of Glasgow, Glasgow, Glasgow, United Kingdom
  • Mark, Patrick Barry, University of Glasgow, Glasgow, Glasgow, United Kingdom
  • Hughes, Jeremy, The University of Edinburgh The Queen's Medical Research Institute, Edinburgh, Edinburgh, United Kingdom
  • Denby, Laura, The University of Edinburgh The Queen's Medical Research Institute, Edinburgh, Edinburgh, United Kingdom
  • Conway, Bryan, The University of Edinburgh The Queen's Medical Research Institute, Edinburgh, Edinburgh, United Kingdom
  • Mylonas, Katie J., The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom
  • Ferenbach, David A., The University of Edinburgh Centre for Inflammation Research, Edinburgh, Edinburgh, United Kingdom

Group or Team Name

  • Ferenbach.
Background

Epithelial senescence is proposed as a driver of kidney fibrosis with senescent cell (SC) depletion improving outcomes. There are no non-invasive biomarkers for quantifying renal SCs. We used samples from patients with kidney disease and cultured human renal proximal tubular epithelial cells (hRPTECs) to identify urinary biomarkers of renal tubular senescence (rtSCs).

Methods

hRPTEC senescence was induced in vitro using 10Gy irradiation. Bulk RNAseq was performed comparing SCs with proliferating controls (n=5/group).

Immunofluorescence staining for p21CIP1, Ki67 and tubular markers CD10/CKPAN was performed in human kidney tissue from 131 CKD patients. P21CIP1 (+) / Ki67 (neg) tubular cells were classified as senescent (expressed as % of all tubular cells). In subgroup 1 (collected in Edinburgh, n=51), LC-MS studies were performed on matched urine samples. Proteins qualified as candidate biomarkers if they predicted the level of histological senescence in multivariate linear regression models alongside baseline eGFR, age and ACR and were upregulated in senescence transcriptomically. Candidate biomarkers were validated in subgroup 2 (collected in Glasgow, matching baseline characteristics to subgroup 1, n=53) that had both urine and kidney tissue available.

Results

In vitro: Irradiation increased mRNA levels of CDKN1A and reduced LMNB1 and MKI67 in keeping with senescence induction.

In vivo: rtSCs increased with age (rho = 0.58, p<0.001) and inversely with baseline eGFR (rho = -0.48, p<0.001). 331 proteins were detected by LC-MS. 5 candidate biomarkers were identified; 3 of which remained highly correlated with and predictive of histological senescence in the validation subgroup (fig. 1) [not named pending patent applications].

Conclusion

We have identified and validated 3 urinary biomarkers of senescence. These could aid patient selection for clinical trials of senolytic treatments in kidney disease.

Spearman rank correlation used.

Funding

  • Government Support – Non-U.S.